Skip to main content
AAN.com
Brief Communications
February 22, 2005

Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial

February 22, 2005 issue
64 (4) 713-715

Abstract

Riboflavin, which improves energy metabolism similarly to coenzyme Q10 (CoQ10), is effective in migraine prophylaxis. We compared CoQ10 (3 × 100 mg/day) and placebo in 42 migraine patients in a double-blind, randomized, placebo-controlled trial. CoQ10 was superior to placebo for attack-frequency, headache-days and days-with-nausea in the third treatment month and well tolerated; 50%-responder-rate for attack frequency was 14.4% for placebo and 47.6% for CoQ10 (number-needed-to-treat: 3). CoQ10 is efficacious and well tolerated.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Welch KMA, Levine SR, D’Andrea G, Schultz L, Helpern JA. Preliminary observations on brain energy metabolism in migraine studied by in vivo 31phosphorus NMR spectroscopy. Neurology 1989;39:538–541.
2.
Watanabe H, Kuwabara T, Ohkubo M, Tsuji S, Yuasa T. Elevation of cerebral lactate detected by localized 1H-magnetic resonance spectroscopy in migraine during the interictal period. Neurology 1996;47:1093–1095.
3.
Penn AMW, Lee JWK, Thuillier P, et al. MELAS syndrome with mitochondrial tRNALeu (UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 1992;42:2147–2152.
4.
Nishikawa Y, Takahashi M, Yorifuji S, et al. Long-term coenzyme Q10 therapy for a mitochondrial encephalomyopathy with cytochrome c oxidase deficiency: a 31P NMR study. Neurology 1989;39:399–403.
5.
Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998;50:466–470.
6.
Rozen TD, Oshinsky ML, Gebeline CA, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002;22:137–141.
7.
Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8:1–96.
8.
International Headache Society Committee on Clinical trials in Migraine. Guidelines for controlled trials of drugs in migraine. 1st ed. Cephalagia 1991;11:1–12.
9.
Price DD, Milling LS, Kirsch I, Duff A, Montgomery GH, Nicholls SS. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain 1999;83:147–156.
10.
Shults CW, Beal MF, Fontaine D, Nakano K, Haas RH. Adsorption tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinson patients. Neurology 1998;50:793–795.

Information & Authors

Information

Published In

Neurology®
Volume 64Number 4February 22, 2005
Pages: 713-715
PubMed: 15728298

Publication History

Published online: February 22, 2005
Published in print: February 22, 2005

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

P. S. Sándor, MD
From the Headache and Pain Unit (Drs. Sándor and Agosti, U. Saenger), Neurology Department, University Hospital Zurich; Zurich Hirslanden Headache Center (Dr. Agosti, U. Saenger), Zurich, Switzerland; Department of Neurology (Drs. Schoenen, Di Clemente, Coppola, Fumal, and Magis), CHR Citadelle, Liège; and Department of Biostatistics and Medical Informatics (L. Seidel), CHU Sart Tilman, University of Liège, Liège, Belgium.
L. Di Clemente, MD
From the Headache and Pain Unit (Drs. Sándor and Agosti, U. Saenger), Neurology Department, University Hospital Zurich; Zurich Hirslanden Headache Center (Dr. Agosti, U. Saenger), Zurich, Switzerland; Department of Neurology (Drs. Schoenen, Di Clemente, Coppola, Fumal, and Magis), CHR Citadelle, Liège; and Department of Biostatistics and Medical Informatics (L. Seidel), CHU Sart Tilman, University of Liège, Liège, Belgium.
G. Coppola, MD
From the Headache and Pain Unit (Drs. Sándor and Agosti, U. Saenger), Neurology Department, University Hospital Zurich; Zurich Hirslanden Headache Center (Dr. Agosti, U. Saenger), Zurich, Switzerland; Department of Neurology (Drs. Schoenen, Di Clemente, Coppola, Fumal, and Magis), CHR Citadelle, Liège; and Department of Biostatistics and Medical Informatics (L. Seidel), CHU Sart Tilman, University of Liège, Liège, Belgium.
U. Saenger
From the Headache and Pain Unit (Drs. Sándor and Agosti, U. Saenger), Neurology Department, University Hospital Zurich; Zurich Hirslanden Headache Center (Dr. Agosti, U. Saenger), Zurich, Switzerland; Department of Neurology (Drs. Schoenen, Di Clemente, Coppola, Fumal, and Magis), CHR Citadelle, Liège; and Department of Biostatistics and Medical Informatics (L. Seidel), CHU Sart Tilman, University of Liège, Liège, Belgium.
A. Fumal, MD
From the Headache and Pain Unit (Drs. Sándor and Agosti, U. Saenger), Neurology Department, University Hospital Zurich; Zurich Hirslanden Headache Center (Dr. Agosti, U. Saenger), Zurich, Switzerland; Department of Neurology (Drs. Schoenen, Di Clemente, Coppola, Fumal, and Magis), CHR Citadelle, Liège; and Department of Biostatistics and Medical Informatics (L. Seidel), CHU Sart Tilman, University of Liège, Liège, Belgium.
D. Magis, MD
From the Headache and Pain Unit (Drs. Sándor and Agosti, U. Saenger), Neurology Department, University Hospital Zurich; Zurich Hirslanden Headache Center (Dr. Agosti, U. Saenger), Zurich, Switzerland; Department of Neurology (Drs. Schoenen, Di Clemente, Coppola, Fumal, and Magis), CHR Citadelle, Liège; and Department of Biostatistics and Medical Informatics (L. Seidel), CHU Sart Tilman, University of Liège, Liège, Belgium.
L. Seidel, MSc
From the Headache and Pain Unit (Drs. Sándor and Agosti, U. Saenger), Neurology Department, University Hospital Zurich; Zurich Hirslanden Headache Center (Dr. Agosti, U. Saenger), Zurich, Switzerland; Department of Neurology (Drs. Schoenen, Di Clemente, Coppola, Fumal, and Magis), CHR Citadelle, Liège; and Department of Biostatistics and Medical Informatics (L. Seidel), CHU Sart Tilman, University of Liège, Liège, Belgium.
R. M. Agosti, MD
From the Headache and Pain Unit (Drs. Sándor and Agosti, U. Saenger), Neurology Department, University Hospital Zurich; Zurich Hirslanden Headache Center (Dr. Agosti, U. Saenger), Zurich, Switzerland; Department of Neurology (Drs. Schoenen, Di Clemente, Coppola, Fumal, and Magis), CHR Citadelle, Liège; and Department of Biostatistics and Medical Informatics (L. Seidel), CHU Sart Tilman, University of Liège, Liège, Belgium.
J. Schoenen, MD, PhD
From the Headache and Pain Unit (Drs. Sándor and Agosti, U. Saenger), Neurology Department, University Hospital Zurich; Zurich Hirslanden Headache Center (Dr. Agosti, U. Saenger), Zurich, Switzerland; Department of Neurology (Drs. Schoenen, Di Clemente, Coppola, Fumal, and Magis), CHR Citadelle, Liège; and Department of Biostatistics and Medical Informatics (L. Seidel), CHU Sart Tilman, University of Liège, Liège, Belgium.

Notes

Address correspondence and reprint requests to Dr. med. Peter S. Sándor, Headache and Pain Unit, Neurology Department, University Hospital Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Approach to headache disorders and the management of migraine: consensus guidelines from the Headache Society of Singapore, first edition (2023), Singapore Medical Journal, (2023).https://doi.org/10.4103/singaporemedj.SMJ-2022-195
    Crossref
  2. Targeting Glutamate Neurotoxicity through Dietary Manipulation: Potential Treatment for Migraine, Nutrients, 15, 18, (3952), (2023).https://doi.org/10.3390/nu15183952
    Crossref
  3. Calcitonin Gene-Related Peptide-Mediated Trigeminal Ganglionitis: The Biomolecular Link between Temporomandibular Disorders and Chronic Headaches, International Journal of Molecular Sciences, 24, 15, (12200), (2023).https://doi.org/10.3390/ijms241512200
    Crossref
  4. Metabolic markers of short and long-term exogenous DL-beta-hydroxybutyrate supplementation in episodic migraine patients: an exploratory analysis of a randomized-controlled-trial, Frontiers in Pharmacology, 14, (2023).https://doi.org/10.3389/fphar.2023.1172483
    Crossref
  5. The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression, The Journal of Headache and Pain, 24, 1, (2023).https://doi.org/10.1186/s10194-023-01587-0
    Crossref
  6. Involvement of Coenzyme Q10 in Various Neurodegenerative and Psychiatric Diseases, Biochemistry Research International, 2023, (1-11), (2023).https://doi.org/10.1155/2023/5510874
    Crossref
  7. Defining metabolic migraine with a distinct subgroup of patients with suboptimal inflammatory and metabolic markers, Scientific Reports, 13, 1, (2023).https://doi.org/10.1038/s41598-023-28499-y
    Crossref
  8. Magnesium and migraine, Treatments, Nutraceuticals, Supplements, and Herbal Medicine in Neurological Disorders, (421-439), (2023).https://doi.org/10.1016/B978-0-323-90052-2.00015-9
    Crossref
  9. Cyclic Vomiting Syndrome, Abdominal Migraine, and Chronic Nausea, Pediatric Neurogastroenterology, (495-507), (2023).https://doi.org/10.1007/978-3-031-15229-0_38
    Crossref
  10. Coenzyme Q10: Current OverviewKoenzim Q10: Güncel Genel Bakış, Türk Kadın Sağlığı ve Neonatoloji Dergisi, 4, 2, (77-86), (2022).https://doi.org/10.46969/EZH.1002286
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share